P052 Nemolizumab elicits rapid itch-free state and sleep improvement in prurigo nodularis

作者：Andrew Pink, Jonathan I. Silverberg, Sonja Ständer, Sarina B. Elmariah, Gil Yosipovitch, Martin Metz, Franz J. Legat, Maxwell Sauder, Brian Kim, Carla S da Silva Santos, Xiaoxiao Chen, Zarif K. Jabbar‐Lopez, Aliene Noda, Christophe Piketty, Shawn G. Kwatra · 发表于：British Journal of Dermatology · 年份：2025 · DOI：10.1093/bjd/ljaf085.080 · 被引用次数：1 · 研究领域：Dermatology and Skin Diseases、Urticaria and Related Conditions、Contact Dermatitis and Allergies

Abstract There is a need for rapid management of the debilitating symptoms of prurigo nodularis (PN), particularly the characteristically severe pruritus. Nemolizumab blocks interleukin (IL)-31, the first neuroimmune cytokine described to directly trigger pruritus. IL-31 also has an important role in inflammatory pathways, epidermal dysregulation and fibrotic responses. We analysed data from the pivotal phase III randomized controlled trials, OLYMPIA 1 and 2, to characterize the onset of action on additional pruritus metrics and sleep disturbances in patients with moderate-to-severe PN. In OLYMPIA 1 and 2 combined, 560 adult patients were randomized to receive an initial 60-mg dose of nemolizumab subcutaneously followed by nemolizumab 30 mg or 60 mg (depending on weight) (n = 373) or matching placebo (n = 187) every 4 weeks for 16 weeks (OLYMPIA 2) or 24 weeks (OLYMPIA 1). We analysed the daily response rates on itch-free or nearly itch-free status and a clinically meaningful improvement (≥ 4-point improvement from baseline) on daily Peak Pruritus Numerical Rating Scale (PP-NRS) and Sleep Disturbance Numerical Rating Scale (SD-NRS). Nearly itch free was defined as a mean daily PP-NRS < 2. By day 4, the proportion of itch-free or nearly itch-free patients was significantly greater with nemolizumab (5.5–6.8%) than with placebo (0–1.3%) in OLYMPIA 1 and 2 (P < 0.05). Further, in a pooled analysis of OLYMPIA 1 and 2, the proportion of patients with ≥ 4-point improve...